Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Dapagliflozin-Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
Anna V Naumova1, Guilherme Moura Cunha1, Nicole J Kim2
1Department of Radiology, University of Washington, Seattle, Washington, USA.
Objective:
This study aimed to investigate the association between SGLT2 inhibitor (dapagliflozin) use in patients with type 2 diabetes (T2D) and changes in body weight and liver fat.
Methods:
This is a secondary analysis of a randomized placebo-controlled trial. Fifty-six patients with T2D were randomized to placebo or 10 mg dapagliflozin. Anthropometrics, liver MRI-proton density fat fraction (PDFF), fasting glucose, HbA1c, and liver function tests were measured at baseline and at 12 months. The relationship between dapagliflozin use and changes in body weight and liver fat was investigated using multiple linear regression models and mediation analysis.
Results:
In this cohort, 76% of participants had hepatic steatosis. Groups were similar in cardiometabolic risk factors and in liver fat fraction values. Compared to placebo, dapagliflozin resulted in reduction in liver MRI-PDFF (-3.7% vs. 0.5%, p = 0.001), body weight (-3.84 vs. -1.42 kg, p = 0.015), and HbA1c (-0.52 vs. 0.11, p = 0.012). Mediation analysis confirmed the direct effect of the SGLT2 inhibitor on change in liver fat and showed that the indirect effect of weight loss on change in liver fat was not statistically significant.
Conclusions:
Twelve months of dapagliflozin was associated with a significant reduction in liver fat as measured by MRI-PDFF compared to placebo; this effect was independent of weight loss and other known beneficial metabolic effects of SGLT2 inhibition.
Trial Registration:
ClinicalTrials.gov: NCT03782259.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Loss of Carboxy Group as CO2: Decarboxylation of β-Ketoacids
Loss of Carboxy Group as CO2: Decarboxylation of Malonic Acid Derivatives
Oxidation-Reduction Reactions
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:

